Long-term treatment with panitumumab monotherapy for recurrent colorectal cancer

Koji Ando, Eiji Oki, Hiroshi Saeki, Yuichiro Nakashima, Yoshihiko Maehara

研究成果: ジャーナルへの寄稿記事

抄録

With the development of new chemotherapy agents and methods, metastatic colorectal cancer patients can now achieve a survival time of >30 months. Higher line therapies have had a significant influence on the survival of these patients. However, it remains uncertain as to which therapy is the most effective and best tolerated. Herein, we describe the case of a patient with metastatic KRAS wild-type colorectal cancer who received panitumumab monotherapy as a third-line therapy after failure of 5-fluorouracil, irinotecan, oxaliplatin and bevacizumab. This patient had both lymph node and lung recurrence. The patient achieved a partial response time of 15 months. The lymph node and recurrent lung tumor had shrunk by 74 and 100 %, respectively, and the treatment was well tolerated with limited cutaneous toxicity. Panitumumab monotherapy may be an effective and well-tolerated treatment of KRAS wild-type metastatic colorectal cancer patients who have undergone many prior therapies. The present case showed a response to panitumumab monotherapy extending over a period of >1 year.
元の言語英語
ページ(範囲)151
ページ数154
ジャーナルInternational Cancer Conference Journal
4
発行部数3
出版物ステータス出版済み - 7 2015

Fingerprint

Colorectal Neoplasms
oxaliplatin
irinotecan
Therapeutics
Lymph Nodes
Lung
Survival
Fluorouracil
Reaction Time
panitumumab
Recurrence
Drug Therapy
Skin
Neoplasms

これを引用

Long-term treatment with panitumumab monotherapy for recurrent colorectal cancer. / Ando, Koji; Oki, Eiji; Saeki, Hiroshi; Nakashima, Yuichiro; Maehara, Yoshihiko.

:: International Cancer Conference Journal, 巻 4, 番号 3, 07.2015, p. 151.

研究成果: ジャーナルへの寄稿記事

@article{594da31ee8de4cf8a985ed8f08bcb174,
title = "Long-term treatment with panitumumab monotherapy for recurrent colorectal cancer",
abstract = "With the development of new chemotherapy agents and methods, metastatic colorectal cancer patients can now achieve a survival time of >30 months. Higher line therapies have had a significant influence on the survival of these patients. However, it remains uncertain as to which therapy is the most effective and best tolerated. Herein, we describe the case of a patient with metastatic KRAS wild-type colorectal cancer who received panitumumab monotherapy as a third-line therapy after failure of 5-fluorouracil, irinotecan, oxaliplatin and bevacizumab. This patient had both lymph node and lung recurrence. The patient achieved a partial response time of 15 months. The lymph node and recurrent lung tumor had shrunk by 74 and 100 {\%}, respectively, and the treatment was well tolerated with limited cutaneous toxicity. Panitumumab monotherapy may be an effective and well-tolerated treatment of KRAS wild-type metastatic colorectal cancer patients who have undergone many prior therapies. The present case showed a response to panitumumab monotherapy extending over a period of >1 year.",
author = "Koji Ando and Eiji Oki and Hiroshi Saeki and Yuichiro Nakashima and Yoshihiko Maehara",
year = "2015",
month = "7",
language = "English",
volume = "4",
pages = "151",
journal = "International Cancer Conference Journal",
issn = "2192-3183",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Long-term treatment with panitumumab monotherapy for recurrent colorectal cancer

AU - Ando, Koji

AU - Oki, Eiji

AU - Saeki, Hiroshi

AU - Nakashima, Yuichiro

AU - Maehara, Yoshihiko

PY - 2015/7

Y1 - 2015/7

N2 - With the development of new chemotherapy agents and methods, metastatic colorectal cancer patients can now achieve a survival time of >30 months. Higher line therapies have had a significant influence on the survival of these patients. However, it remains uncertain as to which therapy is the most effective and best tolerated. Herein, we describe the case of a patient with metastatic KRAS wild-type colorectal cancer who received panitumumab monotherapy as a third-line therapy after failure of 5-fluorouracil, irinotecan, oxaliplatin and bevacizumab. This patient had both lymph node and lung recurrence. The patient achieved a partial response time of 15 months. The lymph node and recurrent lung tumor had shrunk by 74 and 100 %, respectively, and the treatment was well tolerated with limited cutaneous toxicity. Panitumumab monotherapy may be an effective and well-tolerated treatment of KRAS wild-type metastatic colorectal cancer patients who have undergone many prior therapies. The present case showed a response to panitumumab monotherapy extending over a period of >1 year.

AB - With the development of new chemotherapy agents and methods, metastatic colorectal cancer patients can now achieve a survival time of >30 months. Higher line therapies have had a significant influence on the survival of these patients. However, it remains uncertain as to which therapy is the most effective and best tolerated. Herein, we describe the case of a patient with metastatic KRAS wild-type colorectal cancer who received panitumumab monotherapy as a third-line therapy after failure of 5-fluorouracil, irinotecan, oxaliplatin and bevacizumab. This patient had both lymph node and lung recurrence. The patient achieved a partial response time of 15 months. The lymph node and recurrent lung tumor had shrunk by 74 and 100 %, respectively, and the treatment was well tolerated with limited cutaneous toxicity. Panitumumab monotherapy may be an effective and well-tolerated treatment of KRAS wild-type metastatic colorectal cancer patients who have undergone many prior therapies. The present case showed a response to panitumumab monotherapy extending over a period of >1 year.

M3 - Article

VL - 4

SP - 151

JO - International Cancer Conference Journal

JF - International Cancer Conference Journal

SN - 2192-3183

IS - 3

ER -